References
- Chaw CS, Tan CW, Yang YY, Wang L, Moochhala S. Design of physostigmine-loaded polymeric microparticles for pretreatment against exposure to organophosphate agents. Biomaterials 2003; 24: 1271–1277
- Chokshi RJ, Sandhu HK, Iyer RM, Shah NH, Malick AW, Zia H. Characterization of physico-mechanical properties of indomethacin and polymer to access their suitability for hot-melt extrusion process as a mean to manufacture solid dispersion/solution. J Pharm Sci 2005; 94: 2463–2474
- Fahr A, Seelig J. Liposomal formulations of cyclosporin A: A biophysical approach to pharmacokinetics and pharmacodynamics. Crit Rev Therapeutics Drug Carrier Syst 2001; 18: 141–172
- Gref R, Quellec P, Sanchez A, Calvo P, Dellacherie E, Alonso M. Development and characterisation of CyA-loaded poly (lactic acid)-poly(ethylene glycol) micro- and nanoparticles. Comparison with conventional PLA particulates carrier. Eur J Pharm Biopharm 2001; 51: 111–118
- Ismailos G, Peppas C, Dressman J, Macheras P. Unusual solubility behaviour of cyclosporin A in aqueous media. J Pharm Pharmacol 1991; 43: 287–289
- Ismailos G, Peppas C, Macheras P. Enhancement of Cyclosporin-A solubility by D-alphatocopheryl-polyethylene-glycol-1000 succinate (TPGS). Eur J Pharm Sci 1992; 1: 269–271
- Lampen A, Christians U, Bader A, Hackbarth I, Sewing KF. Drug interactions and inter-individual variability of cyclosporin metabolism in the small intestine. Pharmacology 1996; 52: 159–168
- Li XN, Benjamin I, Alexander B. A new rat model of portal hypertension induced by intra-portal injection of microspheres. World J Gastroenterol 1998; 4: 66–69
- Molpeceres J, Aberturas MR, Guzman M. Biodegradable nanoparticles as a delivery system for cyclosporin: Preparation and characterization. J Microencapsulation 2000; 17: 599–614
- Painter PC, Coleman M. Fundamentals of polymer science, an introductory text. 2nd ed. CRC Press, New York 1997
- Pavek P, Fendrich Z, Staud F, Malakova J, Brozmanova H, Laznicek M, Semecky V, Grundmann M, Palicka V. Influence of p-glycoprotein on the transplacental passage of cyclosporine. J Pharm Sci 2001; 90: 1583–1592
- Raderer M, Scheithauer W. Clinical trials of agents that reverse multi-drug resistance. Cancer 1993; 72: 3553–3563
- Shi M, Yang YY, Chaw CS, Goh SH, Moochhala SM, Ng S, Heller J. Double walled POE/PLGA microspheres: Encapsulation of water-soluble and water-insoluble proteins and their release properties. J Contr Rel 2003; 89: 167–177
- Tan KK, Trull AK, Uttridge JA, Wallwork J. Relative bioavailability of cyclosporin from conventional and microemulsion formulations in heart-lung transplant candidates with cystic fibrosis. Eur J Clin Pharmacol 1995; 48: 285–289
- Urata T, Arimori K, Nakano M. Modification of release rates of cyclosporine A from poly (L-lactic acid) microspheres by fatty acid esters and in-vivo evaluation of the microspheres. J Contr Rel 1999; 58: 133–141
- Wang L, Chaw CS, Yang YY, Moochhala SM, Zhao B, Ng S, Heller J. Preparation, characterization, and in vitro evaluation of physostigmine-loaded poly(ortho ester) and poly(ortho ester)/poly(D,L-lactide-co-glycolide) blend microspheres fabricated by spray drying. Biomaterials 2004; 25: 3275–3282
- Woo JS, Piao MG, Li DX, Ryu DS, Choi JY, Kim JA, Kim JH, Jin SG, Kim DD, Lyoo WS, et al. Development of cyclosporin A-loaded hyaluronic microsphere with enhanced oral bioavailability. Int J Pharm 2007; 34: 134–141